Main Content
latest…
Organigram is still undervalued, PI Financial says
Following the company's third quarter results, PI Financial analyst Jason Zandberg is maintaining … Keep reading
More recent headlines
Cannabis
Organigram is still undervalued, PI Financial says
Following the company's third quarter results, PI Financial analyst Jason Zandberg is maintaining his "Buy" rating on Organigram (Organigram News … Read More
See related
Stock Picks
Greenlane Renewables is a buy, Beacon Securities says
Beacon Securities analyst Ahmad Shaath says Greenlane Renewables (Greenlane Renewables News, Stock Quote, Chart TSXV:GRN) is a cleantech junior that … Read more
See related
Life Sciences Stocks
Medexus is Canada’s best specialty pharma stock, Mackie Research says
Following the company's fourth quarter results, Mackie Research Capital analyst André Uddin is … Keep reading
Sernova Corporation has an upside of 317 per cent, Echelon says
Impressive interim outcome data from Sernova Corporation (Sernova Corporation News, Stock Quote, … Keep reading
Time to hop on board Acasti Pharma, says Mackie Research
With its best-in-class omega-3 drug CaPre currently in Phase III trials, Acasti Pharma (Acasti … Keep reading
Medicenna Therapeutics has a 110 per cent upside, says Mackie Research
Investors should be thinking about clinical-stage biotech company Medicenna Therapeutics (Medicenna … Keep reading
Antibe Therapeutics has loads of upside, says Echelon Wealth
Echelon Wealth Partners analyst Douglas Loe is staying bullish on clinical stage drug developer … Keep reading
